BioMarin discontinues VOXZOGO development for Noonan syndrome

BIOMARIN PHARMACEUTICAL INC

Decision announced Sept 15, 2026; development halted for Noonan syndrome indication.
Cites study feasibility and current treatment landscape as reasons.
Company states decision not related to safety or efficacy of VOXZOGO.

item 8.01

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001628280-26-061973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.